Half yearly report is due out in late August along with a shareholders update.
My thoughts are that the stock has to be rerated as it could not be as bad as last year ($10.5M loss).
If the last 6 months turn out to be break even, a run to 30 cents would be expected. New mass market product Patch Express due out in the next 2 months. But then again the microarray units, released last year, were also to be a mass market product (but were not!)
Huntley has them rated as a speculative accumulate in his latest review. He has been a "believer" since day one and it ain't been pretty.
